Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 11/20 | 0.37 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23663370 | 1.00 | MAPT (0.47) | MAPTP2RX3P2RX2KDM4EGAA | |
| SCHEMBL29965239 | 0.86 | P2RX3 (0.34) | MAPTP2RX3P2RX2POLBMEN1 | |
| SCHEMBL23663414 | 0.86 | P2RX3 (0.34) | MAPTP2RX3P2RX2POLBMEN1 | |
| SCHEMBL26420740 | 0.84 | MAPT (0.48) | MAPTP2RX3P2RX2KDM4EGAA | |
| SCHEMBL29965587 | 0.81 | MAPT (0.46) | MAPTP2RX3P2RX2KDM4EGAA | |
| SCHEMBL23663261 | 0.81 | MAPT (0.46) | MAPTP2RX3P2RX2KDM4EGAA | |
| SCHEMBL26401753 | 0.80 | MAPT (0.40) | MAPTPOLBNPC1MEN1ALDH1A1 | |
| SCHEMBL23691429 | 0.80 | MAPT (0.45) | MAPTP2RX3P2RX2KDM4EGAA | |
| SCHEMBL23663408 | 0.78 | MAPT (0.66) | MAPTKDM4EGAAPOLBMEN1 | |
| SCHEMBL23691576 | 0.77 | MAPT (0.42) | MAPTP2RX3P2RX2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-115244037-B | Substituted triazinones as thyroid hormone receptor agonists | 诚益生物(美国)公司 | 2024-10-25 | — | — | CN | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| EP-4090652-A1 | SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS | Eccogene (Shanghai) Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | MAPT 112/4885P2RX3 895/4885P2RX2 1053/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | MAPT 112/4885P2RX3 895/4885P2RX2 1053/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | MAPT 112/4885P2RX3 895/4885P2RX2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.